If you're reading this as a biostatistician or clinical trial professional, you know that the pharmaceutical industry is shifting from classical to adaptive clinical trial design in an effort to reduce NDA failure rate, lower the cost of research and development, and expedite the precision medicine movement. As a member of the Talent & Culture team at Veristat (a CRO), I spend a great deal of time speaking with people like yourself, many of whom are potential candidates excited about the opportunity to work at a company where they may get exposure to an adaptive design trial. Realizing the consistency across these conversations, I have begun wondering if their interest in adaptive designs is a result of it being a current trends, or if it is because adaptive design truly offers increased efficiencies. As a result, I have spent some time research when adaptive design might not be right for a clinical trial and have found two articles that discuss when it is appropriate to use them.

Veristat joined over 6500+ life sciences professionals at the Drug Information Associations (DIA) Annual Meeting  that recently took place in Philadelphia, PA. The conference featured over 175 topics in 25 tracks covering the latest innovations, trends, challenges, and solutions faced by drug developers today. The hottest topics of the meeting were related directly to recent industry trends and events, including increased patient safety, the Zika outbreak, harnessing data to find cures, and many more.

Veristat announced today that it is continuing its accelerated growth and geographic expansion with the opening of an office in Raleigh-Durham, North Carolina. In addition to this newly planned North Carolina office, Veristat has additional North American-based offices in Southborough, MA, Cambridge, MA, San Bruno, CA, Montreal, Canada, and its European office in Glasgow, UK. The new office, scheduled to open in the fall of 2016, will support the company’s accelerated growth by engaging an experienced talent pool and providing local support to Veristat’s clients in the area.

Veristat Strengthens Statistical Consulting and Adaptive Design Trial Expertise

Appoints Mark Chang as Senior Vice President of Strategic Statistical Consulting

The Role of Transparency in CRO-Sponsor Partnerships: Enabling Better Collaboration Models

Join Veristat, as well as Chief Medical Officers and R&D Executives from small to mid-sized life science companies at the Chief Medical Officer Summit East 2016 to share ideas, solutions and support for bringing new products through the clinical development process.

Veristat Expands Its Clinical Operations into Europe

Veristat announced today that it has been recognized as one of the top 50 fastest-growing private companies in Massachusetts, taking the #35 slot.   According to Privco[i], there are over 4,000 private firms operating in Massachusetts today.

Don’t miss Paula Wun’s panel discussion on “Editing Considerations for Submission Documents” at the 5^th Annual Regulatory Writing for Product Apporvals Conference.

Join Veristat and industry leaders in regulatory writing and submissions management at the upcoming 5^th Annual Regulatory Writing for Product Approvals Conference to share and discuss the challenges of writing regulatory submissions in a continually changing regulatory environment.